CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.29B, above the global median of $1.18B
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.68BCNY1.29B · vs all stocks (USD)
Revenue (TTM)
1.96BCNY292.11M · vs all stocks (USD)
Profit Margin
-8.64%52-Week Change
-13.27%vs all stocks
Market Capitalization
8.68BCNY1.29B · vs all stocks (USD)
Enterprise Value
10.34BCNY1.54B · vs all stocks (USD)
Forward P/E
16.88xPrice to Sales (TTM)
4.46xPrice to Book (MRQ)
2.12xEnterprise to Revenue
5.28xEnterprise to EBITDA
48.98xGross Margin
18.40%Profit Margin
-8.64%Operating Margin
-5.06%Return on Assets (TTM)
-1.04%Return on Equity (TTM)
-3.44%Revenue (TTM)
1.96BCNY292.11M · vs all stocks (USD)
Revenue per Share (TTM)
1.21CNYUpdated Sep 19, 2026Quarterly Revenue Growth
22.20%Gross Profit (TTM)
373.58MCNY55.72M · vs all stocks (USD)
EBITDA (TTM)
404.45MCNY60.33M · vs all stocks (USD)
Net Income (TTM)
-169.21MCNY-25.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.26%Operating Cash Flow (TTM)
-22.93MCNY-3.42M · vs all stocks (USD)
5-Year Average Dividend Yield
1.27%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-8.81MCNYFY2025 · Dec 31, 2025Revenue
1.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.41BCNYFY2025 · Dec 31, 2025Gross Profit
454.76MCNYFY2025 · Dec 31, 2025Operating Income
-11.28MCNY-1.68M · vs all stocks (USD)
Pre-tax Income
-84.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.66MCNYFY2025 · Dec 31, 2025Net Income
-93.75MCNYFY2025 · Dec 31, 2025EBIT
-56.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
404.45MCNYFY2025 · Dec 31, 2025Research & Development
116.93MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
98.67MCNYFY2025 · Dec 31, 2025Other Operating Expenses
42.61MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
50.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
27.25MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.52BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.52BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-93.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.68MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-385.90MCNYFY2025 · Dec 31, 2025Free Cash Flow
-451.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.26BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-93.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
54.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-163.71MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-183.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-65.21MCNYFY2025 · Dec 31, 2025Purchase of Investments
-51.24MCNYFY2025 · Dec 31, 2025Sale of Investments
46.80MCNYFY2025 · Dec 31, 2025Other Investing Activity
377.28MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
307.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.45BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.39BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-26.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
67.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
103.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.62BSharesUpdated Sep 19, 2026Float Shares
1.07BSharesUpdated Sep 19, 2026% Held by Insiders
46.38%vs all stocks
% Held by Institutions
2.75%vs all stocks
Total Cash (MRQ)
1.08BCNY160.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5740CNYUpdated Sep 19, 2026Total Debt (MRQ)
1.28BCNY190.92M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2678xCurrent Ratio (MRQ)
1.14xBook Value per Share (MRQ)
2.55CNYUpdated Sep 19, 2026Total Assets
7.33BCNY1.09B · vs all stocks (USD)
Total Current Assets
2.83BCNYFY2025 · Dec 31, 2025Total Liabilities
2.30BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.50BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
86.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.22BCNYFY2025 · Dec 31, 2025Cash
1.25BCNYFY2025 · Dec 31, 2025Cash Equivalents
126.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.38BCNYFY2025 · Dec 31, 2025Other Short-term Investments
14.38MCNYFY2025 · Dec 31, 2025Accounts Receivable
424.59MCNYFY2025 · Dec 31, 2025Inventory
901.91MCNYFY2025 · Dec 31, 2025Accounts Payable
783.71MCNYFY2025 · Dec 31, 2025Short-term Debt
1.29BCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.81MCNYFY2025 · Dec 31, 2025Long-term Debt
551.63KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.33MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.62BCNYFY2025 · Dec 31, 2025Retained Earnings
403.43MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.03BCNY750.39M · vs all stocks (USD)
Treasury Stock
177.51MCNYFY2025 · Dec 31, 202552-Week Low
4.87CNYUpdated Sep 19, 202652-Week High
9.09CNYUpdated Sep 19, 202652-Week Change
-13.27%vs all stocks
50-Day MA
5.32CNYUpdated Sep 19, 2026200-Day MA
6.22CNYUpdated Sep 19, 2026Avg 10-Day Volume
23.12MSharesUpdated Sep 19, 2026Avg 30-Day Volume
20.75MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.1100CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -2.14
Altman Z-Score 2.67: safe zoneNotable
Altman Z-Score: 2.67
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.29B, above the global median of $1.18BNotable
Market cap (USD): 1,294,158,959.845Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking